The Habit Restaurants, Inc. (HABT) Reaches $8.85 After 5.00% Down Move; Intersect ENT, Inc. (XENT) Covered By 7 Bulls

January 14, 2018 - By Michael Collier

The stock of The Habit Restaurants, Inc. (NASDAQ:HABT) is a huge mover today! The stock decreased 5.85% or $0.55 during the last trading session, reaching $8.85. About 450,795 shares traded. The Habit Restaurants, Inc. (NASDAQ:HABT) has risen 7.82% since January 14, 2017 and is uptrending. It has underperformed by 8.88% the S&P500.The move comes after 7 months negative chart setup for the $230.32 million company. It was reported on Jan, 14 by Barchart.com. We have $8.41 PT which if reached, will make NASDAQ:HABT worth $11.52M less.

Among 9 analysts covering Intersect ENT (NASDAQ:XENT), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Intersect ENT had 20 analyst reports since August 17, 2015 according to SRatingsIntel. The firm has “Outperform” rating by Northland Capital given on Tuesday, March 29. The stock of Intersect ENT, Inc. (NASDAQ:XENT) earned “Buy” rating by Deutsche Bank on Wednesday, August 2. On Tuesday, September 29 the stock rating was maintained by Piper Jaffray with “Overweight”. Northland Capital maintained the shares of XENT in report on Wednesday, August 2 with “Hold” rating. Canaccord Genuity maintained the shares of XENT in report on Wednesday, September 13 with “Buy” rating. The stock has “Buy” rating by Canaccord Genuity on Thursday, January 4. Canaccord Genuity maintained Intersect ENT, Inc. (NASDAQ:XENT) rating on Thursday, October 1. Canaccord Genuity has “Buy” rating and $26.0 target. Northland Capital downgraded Intersect ENT, Inc. (NASDAQ:XENT) on Wednesday, May 31 to “Market Perform” rating. The rating was maintained by Canaccord Genuity with “Buy” on Wednesday, December 6. The rating was maintained by Canaccord Genuity on Monday, October 16 with “Buy”. See Intersect ENT, Inc. (NASDAQ:XENT) latest ratings:

04/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $43.0 Maintain
02/01/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Upgrade
06/12/2017 Broker: Canaccord Genuity Rating: Buy New Target: $36.0 Maintain
06/11/2017 Broker: BTIG Research Rating: Hold
16/10/2017 Broker: Canaccord Genuity Rating: Buy New Target: $37.0 Maintain
13/09/2017 Broker: Canaccord Genuity Rating: Buy Old Target: $32 New Target: $37 Maintain
21/08/2017 Broker: Piper Jaffray Rating: Buy New Target: $35.0 Maintain
01/08/2017 Broker: Canaccord Genuity Rating: Buy New Target: $32.0000
02/08/2017 Broker: Northland Capital Rating: Hold New Target: $25.0000 Maintain
02/08/2017 Broker: Deutsche Bank Rating: Buy Old Target: $27 New Target: $31 Maintain

The stock decreased 0.87% or $0.3 during the last trading session, reaching $34.35. About 172,479 shares traded. Intersect ENT, Inc. (NASDAQ:XENT) has risen 79.98% since January 14, 2017 and is uptrending. It has outperformed by 63.28% the S&P500.

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. The company has market cap of $1.01 billion. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It currently has negative earnings. The firm is also developing RESOLVE, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting.

Among 10 analysts covering The Habit Restaurants Inc (NASDAQ:HABT), 6 have Buy rating, 0 Sell and 4 Hold. Therefore 60% are positive. The Habit Restaurants Inc had 20 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of The Habit Restaurants, Inc. (NASDAQ:HABT) has “Buy” rating given on Tuesday, November 17 by Tigress Financial. On Monday, September 11 the stock rating was maintained by Cowen & Co with “Hold”. As per Wednesday, August 19, the company rating was upgraded by Raymond James. The firm earned “Outperform” rating on Wednesday, March 2 by Cowen & Co. Stifel Nicolaus upgraded the stock to “Buy” rating in Friday, August 28 report. Stephens maintained the shares of HABT in report on Wednesday, October 11 with “Overweight” rating. The firm has “Market Perform” rating given on Thursday, November 2 by Raymond James. As per Tuesday, September 26, the company rating was downgraded by Wedbush. The firm has “Market Perform” rating given on Thursday, August 3 by Cowen & Co. The rating was maintained by Robert W. Baird with “Buy” on Monday, October 9.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: